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ABSTRACT 19 
Objectives:  20 
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older 21 
people. Contemporary estimates of incidence and prevalence are lacking and no previous 22 
study has assessed treatment patterns at a population level. This study aims to address this.  23 
 24 
Methods: 25 
We extracted anonymised electronic medical records of patients over the age of 40 years 26 
from the Clinical Practice Research Datalink in the period 1990-2016.  Absolute rate of PMR 27 
per 100,000 person-years was calculated and stratified by age, gender, calendar year. 28 
Incidence rate ratios were calculated using a Poisson regression model. Among persons with 29 
PMR, continuous and total duration of treatment with glucocorticoids (GC) were assessed.  30 
 31 
Results: 32 
5,364,005 patients were included who contributed 44 million person-years of follow-up. 33 
42,125 people had an incident diagnosis of PMR during the period. The overall incidence rate 34 
of PMR was 95.9 per 100,000 [95% confidence interval 94.9, 96.8]. The incidence of PMR 35 
was highest in women, older age groups and those living in the South of England. Incidence 36 
appears stable over time. The prevalence of PMR in 2015 was 0.85%. Median (IQR) 37 
continuous GC treatment duration was 15.8 (7.9, 31.2) months. However, around 25% of 38 
patients received more than four years total GC therapy 39 
 40 
Conclusions: 41 
The incidence rates of PMR have stabilised. This is the first population-based study to 42 
confirm that a significant number of patients with PMR receive prolonged treatment with 43 
3 
 
GC; which can carry significant risks. The early identification of these patients should be a 44 
priority in future research.  45 
 46 
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INTRODUCTION 69 
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting older people. 70 
Its impact on patients’ lives can be devastating; causing stiffness, severe pain and significant 71 
impairment to daily activities. 
1
 Glucocorticoids (GCs) remain the mainstay of treatment. 
2
 72 
The incidence and prevalence of PMR vary depending on geography; as latitude increases, so 73 
do PMR rates. 
3
 Previous studies have estimated the prevalence of PMR to lie between 0.1-74 
1% 
4,5
 and incidence between 12 - 113 per 100,000 person years. 
6–8
 The majority of cases of 75 
PMR are treated in primary care (71-84%), 
7,9
 however much of the existing literature is 76 
based on secondary care hospital records. Therefore the burden of disease may have been 77 
underestimated. One large study (Smeeth et al) 
10
 used primary care data to estimate the 78 
incidence of PMR, reporting an overall rate of 84 per 100,000 person years, which  was 79 
increasing with time. However, the final year of data published in this study was 2001 80 
therefore more contemporaneous estimates of national data are needed to guide health service 81 
provision.   82 
PMR is managed with gradually reducing glucocorticoid (GC) therapy, from moderate to low 83 
doses. 
3
 Joint guidance released by the American College of Rheumatology (ACR) and the 84 
European League Against Rheumatism (EULAR) advises GC treatment for most patients 85 
with PMR should end by two years. 
2
 However, it has been suggested a large proportion of 86 
patients experience symptom flare upon cessation, or even reduction, of GC therapy ( a 87 
“symptom tail’). 11 88 
The aims of this study are to quantify the overall incidence and prevalence of PMR in the UK 89 
using a large population-based database and investigate prescribing of GCs in those 90 
diagnosed with PMR.  91 
 92 
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METHODS 93 
Data source and study population 94 
Almost all healthcare in the United Kingdom (UK) is delivered by the National Health 95 
Service (NHS), a public system funded by taxation that provides free, or low-cost, healthcare 96 
to all residents. Around 90% of patient contacts in the UK with the NHS is via primary care 97 
12
  and 98% of people who live in the UK are registered with a General Practice. We utilised 98 
data from the Clinical Practice Research Datalink (CPRD; version July 2017), which contains 99 
data for around 17 million contributing patients within 718 (7.5% of the total) UK general 100 
practices.  This database, containing electronic, coded information collected during the course 101 
of routine healthcare, is representative of the UK population in terms of age, sex and ethnicity 102 
13
 and  has been used extensively for primary care research. 103 
 104 
Incidence 105 
We analysed data collected between 1
st
 January 1990 and 1
st
 January 2016. Patients 106 
contributed data after the latest of four events: 1) the study start date, 2) the date at which 107 
they became forty years old, 3) the date they registered at a participating practice plus six 108 
months, or 4) the date at which the practice was adjudged to reach internal quality standards; 109 
known as the ‘up-to-standard’ date.  110 
The date at which each follow up ended was the earliest of five events: 1) the end of study 111 
period (1st of January 2016), 2) the date when a patient transferred out of a practice, 3) the 112 
date of death, 4) the last date of data collection from the practice, or 5) the date when they 113 
were diagnosed with PMR. 114 
Patients with a Read coded diagnosis of PMR (codes: N20..00 Polymyalgia rheumatica, 115 
N200.00 Giant cell arteritis with polymyalgia rheumatica) in their general practice record 116 
were included as incident cases. The first six months following registration with a practice 117 
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were excluded from the incidence analysis to avoid inclusion of prevalent cases which may 118 
have been incorrectly recorded at the point of registration. 
10
 To improve case ascertainment, 119 
we only considered PMR diagnosis to be valid if patients received at least two prescriptions 120 
for oral glucocorticoids; one within six months of the diagnosis date and the second within 121 
six months of the first prescription. 
10
 Patients could have a diagnosis of both PMR and giant 122 
cell arteritis (GCA). We looked only at the first occurrence of PMR; therefore all subsequent 123 
person-time and diagnostic codes were excluded. This process is summarised in supplement 124 
1.  125 
 126 
Treatment of PMR 127 
To ascertain trends in the management of PMR, we assessed patterns of glucocorticoid (GC) 128 
prescribing in the incident cases of PMR. All GC prescriptions recorded in CPRD using 129 
medications from the British National Formulary (BNF) chapter 6.3.2 “Glucocorticoid 130 
therapy” were included. 14 CPRD contains information about quantity of medication 131 
prescribed, the number of units of medication to be taken each day and prescription duration. 132 
The algorithm used to define duration and dose of GC therapy (detailed in supplement 2) has 133 
been defined elsewhere 
15
 . Kaplan Meier survival methods were used to calculate the median 134 
duration of time from diagnosis until completion of continuous GC therapy. The end of a 135 
treatment course was determined to have occurred when no further GC prescriptions occurred 136 
for 90 days after the calculated duration of the previous prescription. Patients were censored 137 
if they were lost to follow up prior to stopping treatment. The 90-day period was chosen as it 138 
is the same as in previous CPRD based studies of medication use. 
16
 As part of a sensitivity 139 
analysis, we recalculated this duration 1) by increasing the interval between prescriptions to 6 140 
months; or 2) in patients who received a diagnosis with another rheumatological condition 141 
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either prior to PMR diagnosis or in the two years subsequently; or 3) were referred to 142 
secondary care rheumatology services. 143 
 144 
Statistical analysis 145 
Crude incidence rates of PMR were calculated by dividing the total number of new cases by 146 
the total person-years of follow-up per 100,000 person-years. Incidence rates were stratified 147 
by age, gender, region and calendar year. Patient age was grouped into decades. Lexis 148 
expansion, 
17
 was used to calculate incidence rates by year following the study start date of 1
st
 149 
January 1990.  150 
To compare the absolute rate of PMR by patient characteristics we used a Poisson regression 151 
model and calculated incidence rate ratios (IRR) for each covariate, including sex, age, region 152 
and calendar year of diagnosis. Age-adjusted incidences for each covariate were calculated 153 
with direct standardisation, using the sample population structure over the whole study.  154 
For treatment pattern analysis, we calculated the average daily and total dose of GC 155 
prescribed, as well as cumulative treatment time and the total number of prescriptions and 156 
separate treatment courses each patient received. Dosage calculations were made by 157 
converting the strength of all medications to milligrams of prednisolone equivalent using the 158 
BNF conversion tables of equivalent anti-inflammatory doses. 
14
 Results were stratified by 159 
starting GC dose, age and sex.  160 
Point prevalence of PMR was calculated for each calendar year by dividing the total number 161 
of patients who have received a diagnosis of PMR at any time in the past and were alive and 162 
contributing data on 31
st
 December of that year (numerator) by the total number of patients 163 
alive and contributing data on that date (denominator) thereby including incident and 164 
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prevalent cases. As part of sensitivity analysis we recalculated prevalence in patients aged 165 
over 55 years in order to compare to a recent study.
9
 166 
Ethical approval 167 
This study was approved by CPRD’s in-house Independent Scientific Advisory Committee 168 
(ISAC) (protocol number: 17_203RA).  Statistical analyses were conducted using Stata 169 
version 15.1. 
18
 170 
  171 
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RESULTS 172 
Overall incidence 173 
A total of 5,364,005 individuals contributed 43.97 million person-years of follow-up in the 174 
period 1990-2016. The total number of new occurrences of PMR that fulfilled the GC 175 
prescription criteria was 42,145. This equated to 90.4% of the total number of PMR cases 176 
recorded during this time. The overall incidence rate of PMR amongst patients aged 40 years 177 
and over was 95.9 [confidence interval (CI):  94.9, 96.8] per 100,000 person-years (table 1). 178 
Incidence rates were significantly higher at older ages: those aged>70 years were around ten 179 
times (IRR= 9.61 [95% CI 9.25, 9.98]) more likely to have PMR compared to those between 180 
the ages of 50 and 59 years. Females were 67% more likely to develop PMR compared to 181 
males (IRR= 1.67 [1.64-1.71]).  A marked variation in incidence rates by region was found 182 
(figure 1), with rates highest in the South West region of the UK (124.1 [120.6-127.6]) and 183 
lowest in the North East (65 [59.5- 70.9]).  184 
 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
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Table 1: Incidence rates of PMR, with incidence rate ratios, stratified by age, sex and region 197 
 Number of 
events 
Person time at 
risk (100,000 
years) 
Rate per 100,000 (95% 
Confidence Intervals) 
Incidence Rate Ratio 
(95% Confidence 
Intervals) * 
Age 
standardised 
Incidence 
Rate ⁺ ⁺  (per 
100,000 
person years) 
Overall 42,145 439.70 95.9 (94.9, 96.8)   
Age      
40-49 409 129.96 3.2 (2.9, 3.47) 0.11 (0.10, 0.13)   
50-59 3139 113.75 27.6 (26.7, 28.6) Reference  
60-69 9683 91.62 105.7 (103.6, 107.8) 3.80 (3.65, 3.96)   
70-79 17620 64.76 272.1 (268.1, 276.1) 9.61 (9.25, 9.98)   
80+ 10405 33.05 314.9 (308.9, 321) 10.58 (10.17, 11.13)  
Sex      
Male 13,651 212.06 64.4 (63.3, 65.5) Reference  69.22 
Female 28,494 227.64 125.2 (123.7, 126.6) 1.67 (1.64, 1.71) 114.87 
Region      
North East  500 7.69 65 (59.5, 70.9) 0.82 (0.75, 0.90) 62.54 
North West 3843 49.36 77.9 (75.4, 80.4) Reference 77.54 
Yorkshire & 
the Humber 
1286 16.91 76.1 (72.0, 80.3) 0.97 (0.92, 1.04) 73.62 
East Midlands 1461 16.71 87.4 (83.1, 92.0) 1.14 (1.07, 1.21)  86.13 
West Midlands 4207 41.45 101.5 (98.5, 104.6) 1.26 (1.21, 1.32)  98.44 
East of England 4698 38.44 122.2 (118.8, 125.8) 1.56 (1.49, 1.62)  120.41 
South West 4850 39.10 124.1 (120.6, 127.6) 1.45 (1.39, 1.51)  112.96 
South Central 4754 46.70 101.8 (98.9, 104.7) 1.29 (1.24, 1.35)  101.57 
London 2901 40.63 71.4 (68.9, 74.1) 0.97 (0.93, 1.02)  75.76 
South East 
Coast 
5167 43.89 117.7 (114.6, 121) 1.42 (1.36, 1.48)  110.23 
Northern 
Ireland 
991 13.76 72 (67.7, 76.6) 0.93 (0.87, 1.00)  73.06 
Scotland 3154 40.05 78.7 (76.0, 81.5) 1.03 (0.99, 1. 08)  81.51 
Wales 4333 45.01 96.3 (93.5, 99.2) 1.16 (1.11, 1.21)  90.05 
* Adjusted for age, sex, region and year of diagnosis if not stratified as a covariate 
⁺ ⁺  Incidence rate is adjusted by age using overall proportion of person time contributed per 10 year age category 
 198 
Incidence of PMR over time 199 
The variation in incidence rates of PMR over time are displayed in table 2 and figure 2. The 200 
rate of diagnosis of PMR dipped a little after 1990 until 1996 before increasing significantly 201 
until just after the end of the last century; after this the rate of diagnosis of PMR remained 202 
relatively stable between 2003 and 2014.  203 
 204 
 205 
 206 
 207 
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Table 2: Incidence rates of PMR by calendar year 208 
Year Number 
of events 
Person years 
at risk per 
100,000 
Rate per 100,000 
(95% Confidence 
Interval) 
Incidence Rate Ratio 
(95% Confidence 
Interval)* 
Age 
standardised 
Incidence 
Rate** 
Point 
prevalence 
Overall 42,145 439.70 95.9 (94.9, 96.8)   0.84% 
1990 261 3.30 79.2 (70.1, 89.4) Reference  76.3 0.34% 
1991 336 4.54 74 (66.5, 82.3) 0.91 (0.77, 1.07) 69.4 0.38% 
1992 401 5.27 76.1 (69, 83.9) 0.94 (0.80, 1.09) 72.1 0.44% 
1993 464 6.02 77.1 (70.4, 84.4) 0.95 (0.81, 1.10) 71.9 0.49% 
1994 476 6.55 72.7 (66.5, 79.6) 0.90 (0.77, 1.04) 68.4 0.52% 
1995 548 7.06 77.7 (71.4, 84.4) 0.96 (0.83, 1.11) 74 0.57% 
1996 657 8.06 81.5 (75.5, 88) 1.01 (0.87, 1.16) 77.4 0.60% 
1997 754 9.34 80.7 (75.2, 86.7) 1.01 (0.88, 1.17) 77.6 0.62% 
1998 863 10.69 80.7 (75.5, 86.3) 1.01 (0.88, 1.16) 76.5 0.64% 
1999 1239 13.00 95.3 (90.1, 100.8) 1.20 (1.05, 1.38) 91.7 0.66% 
2000 1537 15.85 96.9 (92.2, 101.9) 1.23 (1.08, 1.40) 93.7 0.68% 
2001 1792 17.75 100.9 (96.4, 105.7) 1.28 (1.13, 1.46) 98.1 0.71% 
2002 2131 20.05 106.3 (101.9, 110.9) 1.36 (1.20, 1.55) 103.5 0.74% 
2003 2211 21.49 102.9 (98.7, 107.3) 1.33 (1.17, 1.51) 101.4 0.77% 
2004 2296 22.96 100 (96, 104.2) 1.30 (1.15, 1.48) 98.5 0.79% 
2005 2348 23.73 99 (95, 103) 1.30 (1.14, 1.48) 98 0.80% 
2006 2389 24.12 99.1 (95.2, 103.1) 1.30 (1.15, 1.48) 97.7 0.83% 
2007 2451 24.45 100.3 (96.4, 104.3) 1.32 (1.16, 1.50) 99.7 0.83% 
2008 2495 24.60 101.4 (97.5, 105.5) 1.33 (1.17, 1.51) 100.7 0.85% 
2009 2447 24.64 99.3 (95.5, 103.3) 1.30 (1.15, 1.48) 98.2 0.85% 
2010 2497 24.34 102.6 (98.6, 106.7) 1.35 (1.19, 1.53) 101.6 0.86% 
2011 2379 23.83 99.8 (95.9, 103.9) 1.32 (1.16, 1.50) 99.1 0.87% 
2012 2268 23.50 96.5 (92.6, 100.6) 1.28 (1.12, 1.45) 95.9 0.87% 
2013 2198 22.51 97.6 (93.6, 101.8) 1.29 (1.14, 1.47) 96.8 0.88% 
2014 2037 20.58 99 (94.8, 103.4) 1.30 (1.14, 1.48) 97.2 0.88% 
2015 1603 17.60 91.1 (86.7, 95.6) 1.20 (1.05, 1.36) 89.1 0.85% 
* adjusted for region, age, gender  
** Incidence rate is adjusted by age using overall proportion of person time contributed per 10 year age category 
 209 
Glucocorticoid prescribing in PMR  210 
In total 1,242,841 GC prescriptions were issued to patients after a diagnosis with PMR; of 211 
these 99.9% contained information about quantity of medication prescribed, and 48.3% about 212 
numeric daily dose. The median time taken for patients to stop continuous therapy was 1.31 213 
years [Interquartile range [IQR] 0.65, 2.6] (figure 3). When the treatment gap was increased 214 
to six months, this increased to 1.88 years [0.93, 4.00]. When total GC treatment time was 215 
reviewed, median duration increased further to 1.93 years [0.95, 4.03], meaning around 25% 216 
of patients received more than four years of therapy. Among patients with a rheumatology 217 
diagnosis, or those referred to rheumatology, the median continual duration of GC therapy 218 
was greater at 1.49 [0.73, 3.16] and 1.55 years [IQR 0.79, 3.06] respectively. The median first 219 
and average daily doses of GC received (in milligrams of prednisolone equivalent) were 220 
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15mg [IQR 8, 21] and 6mg [IQR 4, 9] respectively. However, 7,138 (16.9%) patients 221 
received on average greater than 10mg GC per day. The median total dose of GC received (in 222 
grams of prednisolone equivalent) was 4g [IQR 2, 8]. Repeating analyses stratified by initial 223 
GC dose, age and sex was unremarkable, with only patients aged under 50 receiving 224 
significantly fewer prescriptions.  225 
 226 
Prevalence of PMR 227 
The point prevalence of PMR in 2015 amongst patients aged over 40 years was 0.85% (table 228 
2) and was markedly different between males and females (0.6% and 1.16%). Prevalence 229 
increased to 1.7% (95% CI 1.69%, 1.71%) in patients aged over 55 years. 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
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DISCUSSION 246 
Main findings 247 
This study estimates the burden of PMR in the UK to be slightly higher than previously 248 
estimated. In 2015 around one in 120 adults aged over 40 have received a diagnosis of PMR. 249 
Overall, the incidence of PMR during the study period 1990 to 2016 was 95.9 per 100,000 250 
person years [94.9, 96.8]. However, after increasing until 2002, the incidence rate of PMR 251 
has stabilised. Almost 50% of PMR patients received more than two years of GC therapy 252 
following diagnosis, despite guidelines suggesting treatment should have ended.  253 
Strengths and limitations  254 
We have conducted the largest study yet to calculate a true estimate of the current incidence, 255 
prevalence and real-world treatment patterns of patients with PMR. This study uses robust 256 
methodology in a large, established database of patients who are representative of the UK 257 
population. It therefore is likely to be an accurate estimate of the true burden of PMR.  Most 258 
patients with PMR are managed exclusively in primary care, 
7,9
 therefore this is the most 259 
appropriate setting to conduct this study.  260 
A potential limitation is the ascertainment of cases. This was based on medical codes 261 
recorded by the primary care physicians, rather than research classification criteria
19
 as there 262 
isn’t sufficient detail in medical records and therefore CPRD to allow this. Patients may 263 
therefore subsequently be diagnosed with an alternative condition. However, using GC 264 
prescriptions to confirm PMR diagnosis is well established.
10,20
.Greater than 90% of patients 265 
with a diagnosis of PMR received at least two GC prescriptions; showing the diagnosis is 266 
likely to be accurate in the vast majority of patients Furthermore, in the UK diagnoses made 267 
in secondary care are communicated to, and recorded in, primary care. Therefore although 268 
14 
 
this study examined patients in primary care, it will also contain information from secondary 269 
care.  270 
 271 
Comparison to other studies  272 
The highest incidence, 113 per 100,000 patients, previously reported was a study from the 273 
South West of England. 
4
 Although the overall incidence rate we found is lower than this, our 274 
estimate for this region was slightly higher (124.1 [120.6, 127.6]). In the United States, the 275 
most recent estimates of PMR rate reported by Raheel et al 
8
 was 63.9 per 100,000. This is 276 
lower than our figure. However, this study was not conducted in primary care and stricter 277 
diagnostic criteria, rather than codes were used. 
21
 We included patients from a much larger 278 
sample and whilst our PMR definition is not ideal, our estimates are broadly in line with 279 
other studies that have used clinical classification criteria. Therefore we believe that the risk 280 
of misclassification is minimal.  281 
Women were more likely to develop PMR, with a female to male ratio of approximately 2:1, 282 
reflecting previous studies. 
10
  The strong association between older age and risk of 283 
developing PMR has been demonstrated before, with other studies reporting median age at 284 
diagnosis of 70 
9
 or  75 years. 
7
  As rates of frailty, aches, pains,  
22
 and ESR measurements 
30
 285 
increase with age, it is possible that primary care physicians may over diagnose PMR in at 286 
least some of these patients. 287 
The prevalence of PMR has been found to vary between 0.1% and 1% in North Europe and 288 
North America. 
4,23
 The prevalence of 0.85% in 2015 calculated in our study is consistent 289 
with this. In a recent study in a single large GP practice in the south of the UK, Yates et al 
9
 290 
reported a prevalence of 2.27% in those aged 55 years and over. In our data, the prevalence in 291 
15 
 
this group was 1.7%. This discrepancy could be explained by the higher incidence of PMR in 292 
the south and East of the UK. 293 
Given PMR is known to preferentially affect people of Northern European descent, these 294 
results are likely to be generalisable to countries with significant number of people from this 295 
ethnic group. However, the incidence and prevalence figures reported in this study are less 296 
generalisable to countries at lower latitudes, as incidence and prevalence rates have been 297 
found to reduce with decreasing latitude. 
5,24,25
 298 
The incidence of PMR appears higher in the South of the UK compared to the North. This 299 
was also demonstrated by Smeeth et al. 
10
 Genetic associations between specific Human 300 
Leukocyte Antigen molecules and GCA have been found, 
26
 although none yet for PMR. 
27
 301 
However, as no major variation has been found in the genetic make-up of people between 302 
different regions around the UK it is unlikely to be the reason for this difference. 
28
 Other 303 
potential reasons include an association between social class and PMR, a viral aetiological 304 
agent, or environmental differences such as reduced vitamin D levels in the North of the UK 305 
due to less sunlight exposure may lead to vitamin D deficiency being diagnosed 306 
preferentially. 307 
Smeeth et al 
10
 found that the incidence of PMR in the UK was increasing until 2001, which 308 
we replicated. However following this date, the incidence rate plateaued.  309 
With regards to GC therapy, 75% received a first dose between 8-21mg, which corresponds 310 
well to the recommended starting dose of 12.5-25mg. 
2
  The median duration of treatment of 311 
patients with GC in our sample is, however, less than that found by Shbeeb et al in their 312 
recent study into GC prescribing in a cohort of 359 patients with PMR in Olmsted County, 313 
Minnesota 
29
. The median dose prescribed was similar, at around 5mg; but length of 314 
treatment was greater, with only 19% of patients discontinuing therapy in the first year of 315 
16 
 
treatment, compared to 27% in our data. A number of reasons for this difference could be 316 
suggested, for example their patients may represent more severe variants of the condition; 317 
they defined end of treatment as permanent discontinuation of GC therapy rather than a gap 318 
of 90 days or 6 months and their inclusion criteria were stricter.  Therefore some of the 319 
patients included in our study may have gone on to be reclassified with a different condition 320 
and have GC therapy curtailed earlier. Our sensitivity analyses of patients who had a record 321 
of referral to secondary care rheumatology services, confirmed this group had longer 322 
continuous and total treatment. Both studies agreed though that a significant proportion of 323 
patients were subject to prolonged treatment with GCs.  324 
Previous studies have shown that long-term GC treatment increases a person’s risk of a wide 325 
range of medical conditions. 
30
 This is the first study of a large population which confirms the 326 
existence of a prolonged ‘symptom tail’ in PMR; wherein a significant number of patients 327 
receive a higher average daily dose, a larger total dose, more individual prescriptions of GC 328 
and receive their treatment over a longer period of time.  329 
The reason behind this symptom tail could be a more severe subtype of PMR, or a different 330 
underlying diagnosis, for example rheumatoid arthritis, for which referral for secondary care 331 
review may be appropriate. Alternatively, it may represent GCs masking the symptoms of 332 
other comorbidities which flare upon reduction of GC treatment or adrenal insufficiency 333 
following prolonged GC use. 334 
 335 
Conclusion and clinical implications  336 
In conclusion, we have established the burden that PMR places upon the UK health service. 337 
Due to the ageing population, the prevalence of PMR in the UK is increasing although 338 
incidence rates appear to have stabilised. Analysis of high quality routinely collected primary 339 
17 
 
care data has enabled us to confirm that a significant proportion of patients with PMR receive 340 
prolonged treatment with GC, contrary to previously held norms that cure will be achieved 341 
within two years. Long term GC therapy is associated with a number of serious adverse 342 
effects, 
30
 which is both dose 
31
 and duration 
32
 dependent. Early identification of patients 343 
who are likely to be subject to prolonged GC therapy is a priority area for future research. 344 
These patients could then be prioritised for referral to secondary care for consideration of 345 
GC-sparing agents.  346 
 347 
 348 
  349 
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FIGURE LEGENDS 373 
Figure 1 374 
Incidence rates of PMR by region 1990-2016 375 
Figure 2 376 
Overall, male and female incidence of PMR 1990-2016 with 95% confidence intervals 377 
Figure 3 378 
Kaplan-Meier plot showing time to final glucocorticoid prescription, defined as a gap of 379 
greater than 90 days following end of previous prescription  380 
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